Skip to content
Medical Health Aged Care, Mental Health

Monash University Expert: World Mental Health Day, 10 October 2023

Monash University 2 mins read

This year the theme for World Mental Health Day is ‘mental health is a universal right’. An expert in medical treatments for mental health conditions from Monash University is available for comment.

Professor Chris Langmead, Director of the Neuromedicines Discovery Centre, Monash Institute of Pharmaceutical Sciences
Contact: M: +61 (0)417 959083 / E: [email protected] 

  • There have been no new medicines to treat mental health conditions for 50+ years - in order to make real change to the overall quality of life for patients, this must change.     

  • Limited resources/funding invested into research for the discovery and development of novel medicines to treat mental health conditions has hindered progress. 

  • Accessibility is key - when new medicines (including treatments such as psychedelic-assisted therapy) become an option, they must be rigorously assessed from an economic perspective to ensure they are not reserved to only a small number of patients who can afford them. 

The following quotes can be attributed to Professor Langmead:

“Mental health is a basic human right for everyone, yet one in eight people globally are living with a mental health condition. We need new drugs that are safe and more effective than current options, particularly for difficult to treat mental health conditions. But they also need to be affordable for everyone in need, not just small cohorts of the population.

“Since the 1970s there have been extraordinary breakthroughs in medical treatments for many diseases like cancer, diabetes, heart disease and dementia. Yet new medicines to treat mental health conditions have remained stagnant, due in part to limited resources and funding.

“Recently Australia’s Therapeutic Goods Administration (TGA) approved the use of MDMA and psilocybin for the treatment of post-traumatic stress disorder (PTSD) and treatment-resistant depression, respectively. This has opened up really exciting new opportunities for Australia, however there are still major issues to tackle in order for the TGA’s reclassification to benefit those most in need.


Contact details:

Kate Carthew

+61 438 674 814

[email protected]

Media

More from this category

  • Medical Health Aged Care, Women
  • 19/12/2025
  • 16:00
Breast Cancer Network Australia

Affordable access to life extending drug for people with incurable breast cancer.

Key Facts: Tucatinib, a breast cancer drug, will be listed on PBS, saving patients over $4,500 per month The drug is specifically for HER2-positive metastatic breast cancer patients, particularly those with brain metastases Interviews: Larissa King - woman living with breast cancer that has spread to the brain Vicki Durston. BCNA Director Policy, Advocacy and Support Services. People with breast cancer that has spread to the brain will save more than $4500 a month when Tucatinib is listed on the Pharmaceutical Benefits Scheme in the coming weeks. Breast Cancer Network Australia (BCNA) welcomes today’s decision by the Pharmaceutical Benefits Advisory…

  • Medical Health Aged Care
  • 19/12/2025
  • 09:05
Royal Australian College of GPs

RACGP celebrates WA excellence in general practice at awards

The Royal Australian College of General Practitioners (RACGP) WA Faculty has honoured outstanding contributions to general practice at its annual awards ceremony, celebrating leaders, educators, registrars, and practices across the state. The evening provided the opportunity to celebrate the College’s highest honour, the Rose-Hunt Award, awarded during GP25, which was presented to WA GP, Adjunct Associate Professor Frank R Jones, recognising his 45 years of service to general practice, including 40 years at Murray Medical Centre in Mandurah. Professor Jones has worked across rural, procedural, and community settings and held numerous leadership roles within the RACGP, including President, Vice President,…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.